With the interchangeability designation being an ineffective tool in shifting prescriptions from the reference product to a biosimilar, Sandoz has taken a page out of a health plan’s playbook: Going directly to patients, offering them a cash incentive for moving to a biosimilar. Called the Hyrimoz Patient Transition program, Sandoz offers patients a single $200 … Continue reading Sandoz: Patients Get a $200 Debit Card to Switch to Hyrimoz